Mark G. Eller, Ph.D., is a drug development executive with twenty + years experience in pharmaceutical R&D; including leadership of other VP’s and organizations/departments of 50+ employees. Dr. Eller has extensive experience in pre-clinical studies and the design, execution, analysis and reporting of Phase 1, 2 and 3 clinical trials in the U.S. and Europe. His experience also includes preparation of multiple regulatory filings in U.S., Canada and Europe including IND, MAA, NDA, and CTD submissions leading to approvals. Mark has participated in 6 FDA Advisory Committee meetings, twice as a primary presenter. He is co-inventor on 4 patents in drug discovery and development.